Pacific Biosciences of California (STU:P09) ROCE % : 1.74% (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Pacific Biosciences of California ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Pacific Biosciences of California's annualized ROCE % for the quarter that ended in Dec. 2024 was 1.74%.

Pacific Biosciences of California ROCE % Historical Data

The historical data trend for Pacific Biosciences of California's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pacific Biosciences of California ROCE % Chart

Pacific Biosciences of California Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

12.27

-22.97

-18.06

-18.99

-21.31

Pacific Biosciences of California Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-18.61	-18.41	-45.08	-15.96	1.74

Pacific Biosciences of California ROCE % Calculation

Pacific Biosciences of California's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-282.797	/	( ( (1601.094 - 87.142)	+	(1203.727 - 63.316) )	/ 2 )
	=	-282.797	/	( (1513.952	+	1140.411)	/ 2 )
	=	-282.797	/	1327.1815
	=	-21.31 %

Pacific Biosciences of California's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	20.796	/	( ( (1306.497 - 54.057)	+	(1203.727 - 63.316) )	/ 2 )
	=	20.796	/	( ( 1252.44	+	1140.411 )	/ 2 )
	=	20.796	/	1196.4255
	=	1.74 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Pacific Biosciences of California (STU:P09) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Pacific Biosciences of California ROCE % Related Terms

Thank you for viewing the detailed overview of Pacific Biosciences of California's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Pacific Biosciences of California Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pacific Biosciences of California Inc (STU:P09) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

PACB:USA P09:Germany

Address

1305 O’Brien Drive, Menlo Park, CA, USA, 94025

Website

https://www.pacb.com

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.

Pacific Biosciences of California Headlines

No Headlines